BioCentury | Jul 13, 2019
Finance

How crossover, insider support and big money correlated with performance across 1H19 IPOs

...A) 2/6/19 $21.0 NA $92.8 NA Aeglea BioTherapeutics Inc. (NASDAQ:AGLE) 2/6/19 $37.0 $228.9 $197.6 -14% BioLineRx Ltd....
BioCentury | Oct 19, 2018
Clinical News

BioLineRx reports response, survival data for BL-8040, Keytruda combo in pancreatic cancer

...BL-8040 monotherapy for five days, followed by three-week cycles of BL-8040 in combination with Keytruda. BioLineRx...
...second-line treatment of pancreatic cancer. Data from the triple combination cohort are expected in 2H19. BioLineRx...
...BL-8040 in combination with Keytruda to treat metastatic pancreatic cancer. Merck markets PD-1 inhibitor Keytruda. BioLineRx...
BioCentury | Jan 5, 2018
Clinical News

BioLineRx reports additional Phase IIa data for BL-8040 in AML

...response. BioLineRx has previously reported data from the trial (see BioCentury, April 4, 2016 ). BioLineRx...
...Therapeutics Ltd. (Rehovot, Israel) (see BioCentury, Sept. 10, 2012 ). Biokine Therapeutics Ltd., Rehovot, Israel BioLineRx Ltd....
...blood, apoptosis and clinical response Status: Additional Phase IIa data Milestone: NA Elizabeth S. Eaton BL-8040 Biokine Therapeutics Ltd. BioLineRx Ltd. CXC...
BioCentury | Nov 10, 2017
Company News

iPharma gets rights to Boehringer's FAK inhibitor

...853520, a focal adhesion kinase inhibitor. iPharma is a JV formed in August 2016 by BioLineRx Ltd....
...GmbH, Ingelheim, Germany BioLineRx Ltd. (Tel Aviv:BLRX; NASDAQ:BLRX), Modi'in, Israel I-Bridge Capital, China Business: Cancer Chris Lieu BI 853520 BioLineRx Ltd. Boehringer...
BioCentury | Nov 3, 2017
Company News

iPharma gets rights to Boehringer's FAK inhibitor

...853520, a focal adhesion kinase inhibitor. iPharma is a JV formed in August 2016 by BioLineRx Ltd....
...iPharma plans to obtain global rights to additional assets "at or near clinical stages." Chris Lieu BI 853520 BioLineRx Ltd. Boehringer...
BioCentury | Aug 10, 2017
Clinical News

Genentech starts Phase Ib/II evaluating immunotherapy-based combos for pancreatic ductal adenocarcinoma

...Inc. (NASDAQ:HALO). BL-8040 is a CXC chemokine receptor 4 ( CXCR4 ; NPY3R) antagonist from BioLineRx Ltd....
BioCentury | Apr 7, 2017
Finance

Taking notice

...change; $M; Source: BCIQ: BioCentury Online Intelligence Company Date Amount Post-$ 3/31 Mcap % chg BioLineRx Ltd....
BioCentury | Mar 31, 2017
Company News

Agalimmune, BioLineRx deal

...BioLineRx acquired cancer company Agalimmune for $3 million in cash and $3 million in BioLineRx shares...
...inquiries. Agalimmune Ltd. , London, U.K. BioLineRx Ltd. (Tel Aviv:BLRX; NASDAQ:BLRX), Modi'in, Israel Business: Cancer Chris Lieu AGI-134 Agalimmune Ltd. BioLineRx Ltd....
BioCentury | Mar 31, 2017
Financial News

BioLineRx completes follow-on

...Cancer and immunology company BioLineRx Ltd. (Tel Aviv:BLRX; NASDAQ:BLRX) raised $25 million through the sale of 29.4...
...on March 31. Each ADS represents one ordinary share. BioLineRx Ltd. (Tel Aviv:BLRX; NASDAQ:BLRX), Modi'in, Israel Alicia Parker BioLineRx Ltd....
BioCentury | Feb 9, 2017
Clinical News

BL-8040: Ph II started

...first cycle, patients will receive Keytruda on day 1 of each cycle. In January 2016, BioLineRx...
...combination in the Phase IIa COMBAT trial (see BioCentury, Sept. 26, 2016 ). Biokine granted BioLineRx...
...a 2012 deal (see BioCentury, Sept. 10, 2012 ). Biokine Therapeutics Ltd. , Rehovot, Israel BioLineRx Ltd....
Items per page:
1 - 10 of 200
BioCentury | Jul 13, 2019
Finance

How crossover, insider support and big money correlated with performance across 1H19 IPOs

...A) 2/6/19 $21.0 NA $92.8 NA Aeglea BioTherapeutics Inc. (NASDAQ:AGLE) 2/6/19 $37.0 $228.9 $197.6 -14% BioLineRx Ltd....
BioCentury | Oct 19, 2018
Clinical News

BioLineRx reports response, survival data for BL-8040, Keytruda combo in pancreatic cancer

...BL-8040 monotherapy for five days, followed by three-week cycles of BL-8040 in combination with Keytruda. BioLineRx...
...second-line treatment of pancreatic cancer. Data from the triple combination cohort are expected in 2H19. BioLineRx...
...BL-8040 in combination with Keytruda to treat metastatic pancreatic cancer. Merck markets PD-1 inhibitor Keytruda. BioLineRx...
BioCentury | Jan 5, 2018
Clinical News

BioLineRx reports additional Phase IIa data for BL-8040 in AML

...response. BioLineRx has previously reported data from the trial (see BioCentury, April 4, 2016 ). BioLineRx...
...Therapeutics Ltd. (Rehovot, Israel) (see BioCentury, Sept. 10, 2012 ). Biokine Therapeutics Ltd., Rehovot, Israel BioLineRx Ltd....
...blood, apoptosis and clinical response Status: Additional Phase IIa data Milestone: NA Elizabeth S. Eaton BL-8040 Biokine Therapeutics Ltd. BioLineRx Ltd. CXC...
BioCentury | Nov 10, 2017
Company News

iPharma gets rights to Boehringer's FAK inhibitor

...853520, a focal adhesion kinase inhibitor. iPharma is a JV formed in August 2016 by BioLineRx Ltd....
...GmbH, Ingelheim, Germany BioLineRx Ltd. (Tel Aviv:BLRX; NASDAQ:BLRX), Modi'in, Israel I-Bridge Capital, China Business: Cancer Chris Lieu BI 853520 BioLineRx Ltd. Boehringer...
BioCentury | Nov 3, 2017
Company News

iPharma gets rights to Boehringer's FAK inhibitor

...853520, a focal adhesion kinase inhibitor. iPharma is a JV formed in August 2016 by BioLineRx Ltd....
...iPharma plans to obtain global rights to additional assets "at or near clinical stages." Chris Lieu BI 853520 BioLineRx Ltd. Boehringer...
BioCentury | Aug 10, 2017
Clinical News

Genentech starts Phase Ib/II evaluating immunotherapy-based combos for pancreatic ductal adenocarcinoma

...Inc. (NASDAQ:HALO). BL-8040 is a CXC chemokine receptor 4 ( CXCR4 ; NPY3R) antagonist from BioLineRx Ltd....
BioCentury | Apr 7, 2017
Finance

Taking notice

...change; $M; Source: BCIQ: BioCentury Online Intelligence Company Date Amount Post-$ 3/31 Mcap % chg BioLineRx Ltd....
BioCentury | Mar 31, 2017
Company News

Agalimmune, BioLineRx deal

...BioLineRx acquired cancer company Agalimmune for $3 million in cash and $3 million in BioLineRx shares...
...inquiries. Agalimmune Ltd. , London, U.K. BioLineRx Ltd. (Tel Aviv:BLRX; NASDAQ:BLRX), Modi'in, Israel Business: Cancer Chris Lieu AGI-134 Agalimmune Ltd. BioLineRx Ltd....
BioCentury | Mar 31, 2017
Financial News

BioLineRx completes follow-on

...Cancer and immunology company BioLineRx Ltd. (Tel Aviv:BLRX; NASDAQ:BLRX) raised $25 million through the sale of 29.4...
...on March 31. Each ADS represents one ordinary share. BioLineRx Ltd. (Tel Aviv:BLRX; NASDAQ:BLRX), Modi'in, Israel Alicia Parker BioLineRx Ltd....
BioCentury | Feb 9, 2017
Clinical News

BL-8040: Ph II started

...first cycle, patients will receive Keytruda on day 1 of each cycle. In January 2016, BioLineRx...
...combination in the Phase IIa COMBAT trial (see BioCentury, Sept. 26, 2016 ). Biokine granted BioLineRx...
...a 2012 deal (see BioCentury, Sept. 10, 2012 ). Biokine Therapeutics Ltd. , Rehovot, Israel BioLineRx Ltd....
Items per page:
1 - 10 of 200